[{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AVC-101","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Series B Financing","leadProduct":"AVC-101","moa":"||CD123","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"ViroCell Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"AVC-203","moa":"CD19\/CD20","graph1":"Oncology","graph2":"Preclinical","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ AvenCell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AvenCell Therapeutics \/ AvenCell Therapeutics"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"PHARMALOG Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AvenCell Therapeutics \/ PHARMALOG Institute","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ PHARMALOG Institute"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"PHARMALOG Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AvenCell Therapeutics \/ PHARMALOG Institute","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ PHARMALOG Institute"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Allucent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"R-TM123","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AvenCell Therapeutics \/ Allucent","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Allucent"}]